How MetLife Stock Has Been Trading Recently

MetLife (MET) has been relatively range bound recently, with the stock closing at US$78.08. Recent returns show a decline of about 0.7% over the past day and 2.6% over the past week.

Over the past month the stock is up roughly 3.6%, while the past 3 months show a gain of about 0.9%. On a year to date basis, the stock is down around 2.8%, with a 1 year total return of about 0.6%.

Taking it all together, MetLife’s recent pullback over the past week contrasts with its modestly positive 1 year total shareholder return of 0.6% and its stronger multi year total shareholder returns. This suggests that momentum has cooled after a solid run.

If MetLife’s recent moves have you thinking about where else to put fresh capital, this could be a good moment to scan for 20 top founder-led companies

So with MetLife trading around US$78.08, a roughly 50% intrinsic discount estimate and a gap to analyst targets, is the stock still undervalued here or is the market already factoring in future growth?

Most Popular Narrative: 12.6% Undervalued

MetLife’s most followed narrative pegs fair value at about $89.31, above the recent $78.08 close, and builds a case around long term earnings power.

Strong, sustained premium and sales growth in high-potential international markets (Asia, Latin America, EMEA) positions MetLife to capitalize on growing middle-class wealth and increased insurance penetration, supporting robust long-term revenue and top-line growth.

Ongoing investment in digital transformation (AI-driven underwriting, process automation, embedded insurance partnerships, and tech-enabled distribution) enables MetLife to reduce acquisition and operating costs, improve customer engagement and retention, and, over time, boost net margins.

Curious what sits behind that fair value gap? The narrative leans on steady revenue expansion, margin uplift, and a future earnings multiple that differs from today’s setup.

Result: Fair Value of $89.31 (UNDERVALUED)

However, there is still real execution risk if interest margins stay under pressure, or if commercial mortgage losses and reserves weigh more heavily on capital and earnings.

Another View: Market Multiple Sends a Different Signal

The narrative and DCF style work point to upside, but the market’s own pricing tells a tighter story. MetLife trades on a P/E of 14.6x, above both the US Insurance industry at 11.1x and peers at 13.3x, and only slightly below a fair ratio of 14.8x. That mix hints at less obvious upside and more valuation risk if sentiment cools.

For a closer look at how this P/E gap, industry comparisons, and the fair ratio line up, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment appearing mixed, this is a good moment to review the details yourself and consider both sides of the story. You can start with 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If MetLife has your attention, do not stop here. Use this momentum to scout out other stocks that could suit your goals before opportunities move on.

• Target potential bargains by checking companies that screen well for quality and valuation using the 47 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks that meet the yield and stability filters in the 14 dividend fortresses.
• Reduce portfolio stress by focusing on companies that clear the resilience checks in the 68 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.